Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Biological therapies, clinical trials, adult, CLL, elderly, Combination therapy, Clinical Research, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Biological therapies, clinical trials, adult, CLL, elderly, Combination therapy, Clinical Research, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
La Nouvelle Orleans Ballroom AB
(Ernest N. Morial Convention Center)
Moderators:
Inhye E. Ahn, MD, Dana-Farber Cancer Institute
and
Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Roeker: Beigene: Consultancy; Janssen: Consultancy; AbbVie: Consultancy, Divested equity in a private or publicly-traded company in the past 24 months; AstraZeneca: Consultancy; Loxo Oncology: Consultancy, Other: Travel support, Research Funding; Pharmacyclics: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy; Abbott Laboratories: Current equity holder in publicly-traded company; Aptose Biosciences: Research Funding; Ascentage: Consultancy; Qilu Puget Sound Biotherapeutics: Research Funding.
The session includes 6 oral abstracts reporting the efficacy and safety of targeted doublet combinations (ibrutinib plus venetoclax) in CLL.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH